Supriya Lifescience Limited Announces Mr. Rajeev Kumar Jain as CEO & KMP

Supriya Lifescience Ltd. a cGMP compliant company having a well established presence in API Manufacturing with focus in products of various therapeutic segments like - Anti-Histamine, Anti-Allergics, Vitamins, Anaesthetics, AntiAsthmatics etc. has announced appointment of Mr. Rajeev Kumar Jain as Chief Executive Officer (CEO) & Key Managerial Personnel (KMP) w.e.f. October 3, 2022.

Mr. Rajeev Kumar Jain has over 35+ years of rich functional experience in the manufacturing domain of Bulk Drugs, Intermediate and API with a "Safety First, Quality Must and EBIDTA Growth" mindset.

Mr Jain is a Master of Business Administration (Marketing) from Jivaji University, Gwalior and B Sc (PCB) with distinction. Additionally, he has taken part in business seminars and workshops on corporate transformation in China, Germany, and the Netherlands.

He is very skilled and experienced in managing regulations and guidelines, such as those from the USFDA, KFDA, EMA, ANVISA, CDSCO, ISO, PMDA, and IDL CHINA.

During his long span of career he has received various recognitions for his efforts in executing manufacturing excellence and performing due diligence on API units in order to acquire them and turn them into profit centres.

Throughout his career, he has maintained an impeccable record with reputable companies like Morepen Labs Ltd., Ind Swift Labs, Arch Pharma, Trident Group, Max India (DSM), etc.

He has strategic leadership attributes with a global mindset and has demonstrated lead for cross functional teams with end-to-end solutions & managing optimal utilization of Men, Machine & Material.

Rajiv is the right leader for Supriya Lifescience limited," said Dr. Satish Wagh, Chairman & Managing Director. Rajiv's extensive pharma background and shopfloor skills should help Supriya strengthen manufacturing excellence, develop strategic alliances and expand our international sales presence. We believe his strong leadership experience will help take Supriya to the next level of growth."

"I am very excited to be joining the Supriya team," said Rajiv Kumar Jain. "I believe Supriya has a great business model and talented management team that uniquely positions it to capitalize on the changing Pharmaceutical environment. As the industry evolves, I believe Supriya is in a position to reach newer heights with backward integration, focus on R&D, increasing capacity, and capitalizing on CMO/CDMO potential. Our endeavor would be to achieve healthy revenue growth with healthy margins and upgrade to the evolving GMP and EHS standards."

Source : Equity Bulls

Keywords

SupriyaLifescience Appointment CEO KMP